Fusion proteins with an immunoglobulin hinge region linker

Details Fusion proteins with an immunoglobulin hinge region linker Fusion proteins with an immunoglobulin hinge region linker

1997-07-10

2000-12-26

Spector, Lorraine

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Conjugate or complex

424 852, 435 697, 435325, 4352523, 4353201, 530351, 5303873, 530399, 536 234, C07H 2100, C07K 14455, C07K 1900

Patent

active

061654760

ABSTRACT:
The present invention relates to the production and use of fusion proteins with an immunoglobulin hinge region linker.

REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4874813 (1989-10-01), O'Shannessy
patent: 5073627 (1991-12-01), Curtis et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5114711 (1992-05-01), Bell et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5314995 (1994-05-01), Fell, Jr. et al.
patent: 5349053 (1994-09-01), Landolfi
patent: 5428130 (1995-06-01), Capon et al.
patent: 5547852 (1996-08-01), Seiler et al.
patent: 5580853 (1996-12-01), Sytkowski
patent: 5614184 (1997-03-01), Sytkowski et al.
patent: 5672683 (1997-09-01), Friden et al.
patent: 5738849 (1998-04-01), Bauer et al.
patent: 5759536 (1998-06-01), Bellgrau et al.
R. Callard et al., eds. "The Cytokine FactsBook", pp. 41-42. Academic Press, San Diego, 1994.
M.E. Shapiro et al., "In vivo Studies with Chimeric Toxins: Interleukin-2 Fusion Toxins as Immunosuppressive Agents" Targeted Diagn. Ther. 7:383, 1992.
Jelkmann, W., "Biology of erythropoietin", Clin. Investig. 72:S3-S10 (1994).
Yamaguchi, K., et al., "Effects of Site-directed Removal of N-Glycosylation Sites in Human Erythropoietin on Its Production and Biological Properties," J. Biol. Chem., 266(30):20434-20439 (1991).
Boissel, J.P. and Bunn, H.F., "Erythropoietin Structure-Function Relationships," In The Biology of Hematopoiesis, (Wiley-Liss, Inc.), pp. 227-232 (1990).
Dube, S., et al., "Glycosylation at Specific Sites of Erythropoietin Is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263(33):17516-17521 (1988).
Wen, D., et al., "Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals," Blood, 82(5):1507-1516 (1993).
Wen, D., et al., "Erythropoietin Structure-Function Relationships: Identification of Functionally Important Domains," J. Biol. Chem., 269(36):22839-22846 (1994).
Boissel, J-P., et al., "Erythropoietin Structure-Function Relationships: Mutant Proteins That Test A Model of Tertiary Structure," J. Biol. Chem., 268(21):15983-15993 (1993).
Chern, Y., et al., "Potentiation of the Erythropoietin Response by Dimethyl Sulfoxide Priming of Erythroleukemia Cells: Evidence for Interaction of Two Signaling Pathways," Blood, 76(11):2204-2209 (1990).
Sytkowski, A., et al., "Immunochemical Studies of Human Erythropoietin Using Site-Specific Anti-peptide Antibodies: Identification of a Functional Domain," J. Biol. Chem., 262(3):1161-1165 (1987).
Sytkowski, A., et al., "Isolation and Characterization of an Anti-Peptide Monoclonal Antibody to Human Erythropoietin," J. Biol. Chem., 260(27):14727-14731 (1985).
Feldman, L., et al., "Four Unique Monoclonal Antibodies to the Putative Receptor Binding Domain of Erythropoietin Inhibit the Biological Function of the Hormone," Exp. Hematol., 20:64-68 (1992).
Fibi, M.R., et al., "N-and O-Glycosylation Muteins of Recombinant Human Erythropoietin Secreted from BHK-21 Cells," Blood, 85(5):1229-1236 (1995).
Takeuchi, M., et al., "Role of Sugar Chains in the in Vitro Biological Activity of Human Erythropoietin Produced in Recombinant Chinese Hamster Ovary Cells," J. Biol. Chem., 265(21):12127-12130 (1990).
Yonekura, S., et al., "Erythropoietin Receptors Induced By Dimethyl Sulfoxide Exhibit Positive Cooperativity Associated With an Amplified Biologic Response," Proc. Natl. Acad. Sci. USA, 88:2535-2539 (1991).
Grodberg, J., et al., "Functional and Structural Role of Arginine 103 in Human Erythropoietin," Arch. Bioch. Bioph., 333(2):427-431 (1996).
Chern, Y., et al., "Structural Role of Amino Acids 99-110 in Recombinant Human Erythropoietin," Eur. J. Biochem., 202:225-229 (1991).
Grodberg, J., et al., "Alanine Scanning Mutagenesis of Human Erythropoietin Identifies Four Amino Acids Which are Critical for Biological Activity," Eur. J. Biochem., 218:597-601 (1993).
Jacobs, K., et al., "Isolation and Characterization of Genomic and cDNA Clones of Human Erythropoietin," Nature, 313:806-810 (1985).
Hollenbaugh, D., et al., "Cleavable CD40Ig Fusion Proteins and the Binding to sgp39," J. Immuno. Meth., 188:1-7 (1995).
Sandlie, I. and Michaelsen, T.E., "Engineering the Hinge Region to Optimize Complement-induced Cytolysis," In Antibody Engineering, C.A.K. Borrebaeck, eds. (NY: W.H. Freeman and Company) pp. 69-88 (1992).
Hamers-Castermann, C., et al., "Naturally Occurring Antibodies Devoid of Light Chains," Nature, 363:446-448 (1993).
Terskjkh, A.V., et al., "Peptabody: A New Type of High Avidity Binding Protein," Proc. Natl. Acad. Sci. USA, 94:1663-1668 (1997).
McMahon, F.G., et al., "Pharmacokinetics and Effects of Recombinant Human Erythropoietin After Intravenous and Subcutaneous Injections in Healthy Volunteers," Blood, 76(9):1718-1722 (1990).
Spivak, J.L., et al., "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73(1): 90-99, (Jan. 1989).
Knuli, C., et al., "Polyethylene Glycol (PEG) Modification of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Enhances Neutrophil Priming Activity but Not Colony Stimulating Activity," British Journal Haematology, 82:654-663 (1992).
Satake, R., et al., "Chemical Modification of Erythropoietin: An Increase in In Vitro Activity by Guanidination," Biochimica et Biophysica Acta, 1038:125-129 (1990).
Modi, N.B., "Pharmacokinetics and Pharmacodynamics of Recombinant Proteins and Peptides," J. Controlled Release, 29:269-281 (1994).
Batra, J.K., et al., "Insertion of Constant Region Domains of Human IgG into CD4-PE40 Increases its Plasma Half-Life," Mol. Immunology, 30(4):379-386 (1993).
Sytkowski, A.J., et al., "An Epo--Epo Fusion Protein with Enhanced Potency and Efficacy in vivo," Thirty-Ninth Annual Meeting of the American Society of Hematology, San Diego, California, USA, Dec. 5-9, 1997. Blood 90 (Suppl. 1 Part 1). 1997. 57A. (Abstract 244).
Lunn, E.D., et al., "Erythropoietin Dimers with Enhanced in vivo Activity in Mice," Thirty-Eighth Annual Meeting of the American Society of Hematology, Orlando, Florida, USA, Dec. 6-10, 1996. Blood 88 (10 Suppl. 1 Part 1-2). 1996. 543A. (Abstract 2161).
McGary, E.C., et al., "Post-transcriptional Regulation of Erythropoietin mRNA Stability by Erythropoietin mRNA-binding Protein," The Journal of Biological Chemistry, 272:8628-8634 (1997).
Sytkowski, A.J., "Human Erythropoietin Dimers with Markedly Enhanced in vivo Activity," Proc. Natl. Acad. Sci. USA 95:1184-1188 (1998).

Affiliated with

Also associated with

Rating

Fusion proteins with an immunoglobulin hinge region linker does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fusion proteins with an immunoglobulin hinge region linker, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion proteins with an immunoglobulin hinge region linker will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-991777